BlackRock Advisors’s Sage Therapeutics SAGE Stock Holding History

BlackRock Advisors’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$19M	Buy	371,543 +24,118	+7%	+$1.14M	0.02%	592
2016 Q3	$16M	Buy	347,425 +112,559	+48%	+$4.58M	0.02%	624
2016 Q2	$7.08M	Buy	234,866 +114,551	+95%	+$3.82M	0.01%	967
2016 Q1	$3.86M	Buy	120,315 +1,926	+2%	+$67.8K	﹤0.01%	1195
2015 Q4	$6.9M	Sell	118,389 -3,267	-3%	-$162K	0.01%	998
2015 Q3	$5.15M	Sell	121,656 -55,944	-32%	-$3.45M	0.01%	1079
2015 Q2	$13M	Sell	177,600 -111,317	-39%	-$7.16M	0.01%	676
2015 Q1	$14.5M	Buy	288,917 +226,641	+364%	+$9.74M	0.01%	670
2014 Q4	$2.28M	Buy	62,276 +24,526	+65%	+$914K	﹤0.01%	1161
2014 Q3	$1.19M	Buy	+37,750	New	+$1.09M	﹤0.01%	1346

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

ORI

Oak Ridge Investments Chicago, Illinois $1.51B AUM 37.25% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

BlackRock Advisors's SAGE Position: Q4 2016 in Review

BlackRock Advisors increased its Sage Therapeutics (SAGE) stake by 6.9% in Q4 2016, buying an estimated $1.14M and bringing the position to 371,543 shares worth $19M. The position accounts for 0.02% of the portfolio, ranked #592.

BlackRock Advisors first reported a position in SAGE in Q3 2014 and has held it in 10 quarters since. 165 funds tracked by Wall St. Rank hold SAGE as of Q4 2016.

BlackRock Advisors held 371,543 shares of Sage Therapeutics worth $19M as of Q4 2016.
BlackRock Advisors bought 24,118 Sage Therapeutics shares in Q4 2016, an estimated $1.14M.
Sage Therapeutics made up 0.02% of BlackRock Advisors's portfolio in Q4 2016, its #592 holding.
BlackRock Advisors first reported a position in Sage Therapeutics in Q3 2014 and has held it in 10 quarters since.
165 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.